Biomarkers of immunosuppressant organ toxicity after transplantation: Status, concepts and misconceptions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 2, 2011, Pages 175-200

  Christians, Uwe ^a   Klawitter, Jost ^a,b   Klawitter, Jelena ^a   Brunner, Nina ^c   Schmitz, Volker ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Eurofins Medinet Inc   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biomarkers; drug toxicity; immunosuppressants; transplantation

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALBINDIN; CYCLOSPORIN; CYSTATIN C; CYSTEINE RICH PROTEIN 61; ENDOTHELIN 1; FETUIN A; GELATINASE B; GLUTATHIONE TRANSFERASE ALPHA; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; ISOPROSTANE DERIVATIVE; KIDNEY INJURY MOLECULE 1; METHYLPREDNISOLONE; MOLECULAR MARKER; MYCOPHENOLIC ACID; N ACETYL BETA GLUCOSAMINIDASE; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PADGEM PROTEIN; RAPAMYCIN; SERUM AMYLOID A; TACROLIMUS; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANOREXIA; CARDIOTOXICITY; CEREBRAL BLINDNESS; DIARRHEA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM CELL; ENTEROCOLITIS; ERYTHROCYTE; GASTRITIS; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; GENOTYPE; HALLUCINATION; HUMAN; IMMUNOSUPPRESSANT ORGAN TOXICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; INTESTINE VILLUS ATROPHY; METABOLOMICS; MITOCHONDRIAL ENCEPHALOPATHY; NECROSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; PREDICTION; PROTEOMICS; REVIEW; SEIZURE; STOMACH EROSION; STROKE; SYSTEMS BIOLOGY; ULCER;

BIOLOGICAL MARKERS; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLOME; PHENOTYPE; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 79952171650     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.544249     Document Type: Review

References (182)

1. Womer KL, Kaplan B. Recent developments in kidney transplantation - a critical assessment. Am J Transplant 2009;9:1265-71
2. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001;71:SS42-51
3. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporine: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001;61:1957-2016
4. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38
5. Kahan BD. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation 2001;71:SS52-7
6. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000;13:313-16
7. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339-46 (Pubitemid 29261421)
8. Nankivell BJ, Borrows RJ, Fung CLS, et al. The natural history of chronic allograft rejection. N Engl J Med 2003;349:2326-33 (Pubitemid 37509740)
9. Nankivell BJ, Borrow RJ, Fung CLS, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65 This study highlights the clinical importance of immunosuppressant-induced nephrotoxicity and shows that pathologic changes of CsA nephrotoxicity were virtually universal by 10 years after transplantation.
10. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006;81:643-54
11. Trapp A, Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005;45:81-7 A systematic in vitro study assessing the molecular mechanisms of immunosuppressant-induced effects on endothelial cells.
12. Moreno JM, Ruiz MC, Ruiz N, et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005;37:1428-30 (Pubitemid 40716042)
13. Tepperman E, Ramzy D, Prodger J, et al. Vascular effects of immunosuppression. Can J Surg 2010;53:57-63
14. Lexis LA, Fenning A, Brown L, et al. Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. Am J Transplant 2006;6:41-9 (Pubitemid 43382199)
15. Louhelainen M, Merasto S, Finckenberg P, et al. Lipoic acid supplementation prevents cyclosporine-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. J Hypertens 2006;24:947-56 (Pubitemid 43670467)
16. Vaziri ND, Ni Z, Zhang YP, et al. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int 1998;54:482-91 (Pubitemid 28357411)
17. Avdonin PV, Cottet-Maire F, Afanasjeva GV, et al. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999;55:2407-14 (Pubitemid 29256495)
18. Josephine A, Amudha G, Veena CK, et al. Oxidative and nitrosative stress mediated renal cellular damage induced by cyclosporine A: role of sulphated polysaccharides. Biol Pharm Bull 2007;30:1254-9 (Pubitemid 47037648)
19. Wang C, Salahudeen AK. Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E. Kidney Int 1995;47:927-34
20. Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005;79:419-26 (Pubitemid 40280173)
21. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16:1501-11 (Pubitemid 41716536)
22. Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomize multicenter study. Lancet 2000;356:194-202
23. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001;71:1400-6 (Pubitemid 32507112)
24. Klawitter J, Bendrick-Peart J, Rudolph B, et al. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009;22:118-28
25. Serkova N, Christians U. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Invest Drugs 2003;4:1287-96 (Pubitemid 38100573)
26. Christians U, Gottschalk S, Miljus J, et al. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol 2004;143:388-96 (Pubitemid 39424827)
27. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007;39:88-93
28. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997;17:75-92 (Pubitemid 27395573)
29. DeMattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-46 (Pubitemid 30070861)
30. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60 (Pubitemid 30238708)
31. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036-42 (Pubitemid 29200856)
32. Golshayan D, Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transplant Immunol 2008;20:21-8
33. Pretagostini R, Cinti P, Lai Q, et al. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transplant Immunol 2008;20:3-5
34. Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004;10:476-82 (Pubitemid 39620197)
35. Opelz G, Dohler B. Discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008;86:371-6 This registry analysis shows that the reduction of calcineurin inhibitors doses or complete discontinuation during long-term management of transplant patients can adversely affect long-term outcomes.
36. Berl T. American Society of Nephrology Renal Research report. J Am Soc Nephrol 2005;16:1886-903 (Pubitemid 41716419)
37. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006;6:2006-12 (Pubitemid 44199535)
38. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26 An important review that discusses and explains the risks of overlooking transplant kidney dysfunction during its earlier stages as is common with current clinical monitoring strategies. Late identification of chronic allograft dysfunction in individual patients has meant that strategies for intervening to prevent chronic renal allograft dysfunction and subsequent graft loss tend to be 'too little and far too late'.
39. Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today 2005;10:781-8 (Pubitemid 40744922)
40. Stojnev S, Pejcic M, Dolicanin Z, et al. Challenges of genomics and proteomics in nephrology. Ren Fail 2009;31:765-72
41. Christians U, Klawitter J, Bendrick-Peart J, et al. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality and challenges. Ther Drug Monit 2008;30:151-8 (Pubitemid 351521641)
42. Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008;2:387-98 (Pubitemid 351659225)
43. Schnackenberg LK. Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century. Expert Rev Mol Diagn 2007;7:247-59
44. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26
45. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83 This is a comprehensive review of the principles of protein marker development as clinical diagnostic tools and the regulatory approval process.
46. Nobeli I, Thornton JM. A bioinformatician's view of the metabolome. Bioessays 2006;28:534-45 (Pubitemid 43668068)
47. Christians U, McCrery S, Klawitter J, Klawitter J. The role of proteomics in the study of kidney diseases and in the development of diagnostic tools. In: Edelstein CL, editor, Biomarkers of kidney disease. Elsevier, San Diego; 2011
48. Xu EY, Schaefer WH, Xu Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr Opin Drug Discov Devel 2009;12:40-52
49. Christians U, Albuisson J, Klawitter J, Klawitter J. The role of metabolomics in the study of kidney diseases and in the development of diagnostic tools. In: Edelstein CL, editor, Biomarkers of kidney disease. Elsevier, San Diego; 2011
50. Oldiges M, Lutz S, Pflug S, et al. Metabolomics: current state and evolving methodologies and tools. Appl Microbiol Biotechnol 2007;76:495-511 (Pubitemid 47283107)
51. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007;26:51-78 (Pubitemid 46051813)
52. Gowda GA, Zhang S, Gu H, et al. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008;8:617-33
53. Want EJ, Nordstrom A, Morita H, et al. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007;6:459-68 (Pubitemid 46340150)
54. Domon B, Aebersold R. Mass spectrometry in protein analysis. Science 2006;312:212-17
55. Aebersol R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207 (Pubitemid 36362757)
56. de Hoog CL, Mann M. Proteomics. Annu Rev Genomics Hum Genet 2004;5:267-93
57. Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics 2008;7:1850-62
58. Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5:1023-38
59. Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 2007;96:269-98 (Pubitemid 44855852)
60. Burckart GJ, Amur S, Goodsaid FM, et al. Qualification of biomarkers for drug development in organ transplantation. Am J Transplant 2008;8:267-70 This review critically discusses the development of biomarkers and regulatory requirements in the field of organ transplantation.
61. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7 A critical review and discussion of biomarkers in drug development and the related regulatory aspects and challenges.
62. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347-66 This article discusses the FDA's positions and perspectives regarding biomarker development, qualification and approval.
63. Fawcett T. Introduction to ROC analysis. Pattern Recognit Lett 2006;27:861-74
64. Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008;245:219-23
65. Lee JW, Weiner RS, Sailstad JM, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:499-511 (Pubitemid 40603246)
66. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5
67. Rodriguez H, Tezak Z, Mesri M, et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 2010;56:237-43
68. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. (2001) Guidance for the Industry. Bioanalytical Method Validation. Version May 2001. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf [Last accessed 29 August 2010]
69. Clinical and Laboratory Standards Institute. Available from: www.clsi.org [Last accessed 29 August 2010]
70. European Agency for the Evaluation of Medicinal Products (1995) ICH topic Q2 (R1). Validation of analytical procedures: text and methodology. Note for guidance on analytical procedures: text and methodology. CPMP ICH/381/95. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002662.pdf [Last accessed 29 August 2010)
71. United States Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for the Industry. Pharmacogenomic data submissions. March 2005. Available from: http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm126957.pdf [Last accessed 29 August 2010)
72. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (1998). Guidance for Industry: providing clinical evidence of effectiveness for human drug and biological products. Version May 1998. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf [Last accessed 29 August 2010]
73. Nickel T, Schlichting L, Weis M. Drugs modulating endothelial function in transplantation. Transplantation 2006;82(1S):S41-6
74. Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2007;16:506-11 (Pubitemid 350293740)
75. Conti M, Moutereau S, Esmilaire L, et al. Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C. Clin Chem Lab Med 2009;47:1553-6
76. Wishart DS. Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005;5:2814-20 (Pubitemid 43923941)
77. Wishart DS. Metabolomics: a complementary tool in renal transplantation. Contrib Nephrol 2008;160:76-87
78. Lenz EM, Bright J, Knight R, et al. Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLCTOF/MS and chemometrics. J Pharm Biomed Anal 2004;35:599-608 (Pubitemid 38609380)
79. Klawitter J, Haschke M, Kahle C, et al. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 2010;70:241-51 A placebo-controlled clinical trial in healthy individuals showing that 1H-NMR-based metabolic profiling in urine is sensitive enough to detect the negative effect of a single 5 mg/kg cyclosporine dose kidney already within the first hours after oral administration.
80. Schmitz V, Klawitter J, Bendrick-Peart J, et al. Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron 2009;111:e80-91
81. Klawitter J, Klawitter J, Kushner E, et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res 2010;9:865-75 This study links the changes in urinary metabolite patterns after exposure of rats to cyclosporine and/or sirolimus for 28 days to changes in protein expression in the kidney and shows the usefulness of a proteo-metabonomic approach for mechanistic molecular marker qualification.
82. Stapenhorst L, Sassen R, Beck B, et al. Hypocitrateuria as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005;20:652-6 (Pubitemid 41166622)
83. Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005;27:733-7 (Pubitemid 44391725)
84. Kanaby M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005;37:3119-20 (Pubitemid 41435638)
85. Perico N, Codreanu I, Caruso M, et al. Hyperuricemia in kidney transplantation. Contrib Nephrol 2005;147:124-31 (Pubitemid 43264990)
86. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogeneric role in graft dysfunction and hypertension in renal transplant patients? Transplantation 2005;80:1565-71
87. Le Moyec L, Pruna A, Eugene M, et al. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 1993;65:433-9 (Pubitemid 23321243)
88. Foxall PJ, Mellotte GJ, Bending MR, et al. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int 1993;43:234-45 (Pubitemid 23167471)
89. Knoflach A, Binswanger U. Serum hippuric acid concentration in renal allograft rejection, ureter obstruction, and tubular necrosis. Transpl Int 1994;7:17-21 (Pubitemid 24008963)
90. Rush D, Somorjai R, Deslauriers R, et al. Subclinical rejection - a potential surrogate marker for chronic rejection - may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000;5:44-9
91. Wang NJ, Zhou Y, Zhu TY, et al. Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 2008;7:3597-601
92. Voshol H, Brendlen N, Muller D, et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res 2005;4:1192-9 (Pubitemid 41208677)
93. European Medicines Agency, Committee for Medicinal Products for Human Use. Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. January 2009. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural- guideline/2009/10/WC500004205.pdf [Last accessed 31 August 2010]
94. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010;28:478-85
95. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010;28:463-9
96. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28:436-40
97. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008;27:328-39
98. Merrick AB, Bruno ME. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr Opin Mol Ther 2004;6:600-7 (Pubitemid 40074980)
99. Dadhania D, Snopkowski C, Ding R, et al. Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 2010;90:189-97
100. Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010;15:35-41
101. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009;106:5330-5
102. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463-8 A review explaining in detail the potential clinical utility of novel urinary protein markers for the diagnosis and monitoring of acute clinical injury (Table 4) and their potential clinical impact.
103. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002;8:509-14 (Pubitemid 35388204)
104. Lee BT, Liew L, Lim J, et al. Candidate List of yoUr Biomarker (CLUB): a web-based platform to aid cancer biomarker research. Biomark Insights 2008;3:65-71 (Pubitemid 351279847)
105. Sistare F, Dieterle F, Troth S, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 2010;28:446-54
106. Puntman VO. How-to-guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J 2009;85:538-45
107. Biomarkers Definitions Working Group. Biomarker and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
108. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62 (Pubitemid 43947980)
109. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008;134:714-17
110. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006;2:52
111. Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001;36:1083-91 (Pubitemid 33040761)
112. Gallego MJ, Zoja C, Morigi M, et al. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Am J Kidney Dis 1996;28:23-31 (Pubitemid 26231462)
113. Al-Massarani G, Vacher-Coponat H, Paul P, et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008;8:2360-7
114. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009;23:241-8
115. Edwards BS, Hunt SA, Fowler MB, et al. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 1991;67:782-4
116. Ramzy D, Rao V, Tumiati LC, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006;114(1 Suppl):I214-19
117. Muller TF, Vogl M, Neumann MC, et al. Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 1998;276:63-74 (Pubitemid 28386829)
118. Maury CP, Teppo AM, Ahonen J. Posttransplantation monitoring of high-density lipoprotein-associated serum amyloid A protein: a new diagnostic aid in the detection of renal allograft rejection. Uremia Invest 1985;9:277-80 (Pubitemid 16039475)
119. Aukrust P, Halvorsen B, Yndestad A, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008;28:1909-19
120. Sahin G, Akay OM, Kus E, et al. Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients. Ren Fail 2009;31:111-17
121. Aharinejad S, Krenn K, Zuckermann A, et al. Matrix metalloproteases and their tissue inhibitor in cardiac transplantation. Eur J Cardiothorac Surg 2007;32:48-51 (Pubitemid 46874981)
122. Caglar K, Yilmaz MI, Saglam M, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007;83:392-7 (Pubitemid 46667841)
123. Yilmaz MI, Saglam M, Caglar K, et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005;80:1660-6 (Pubitemid 43053988)
124. Nouri-Majalan N, Masoumi R, Nafisi R, et al. Relationship between serum homocysteine and other parameters in renal transplant patients. Transplant Proc 2009;41:2826-8
125. Lexis LA, Fenning A, Brown L, et al. Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. Am J Transplant 2006;6:41-9 (Pubitemid 43382199)
126. Vural A, Yilmaz MI, Caglar K, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005;25:250-5 (Pubitemid 41202747)
127. Betton GR, Kenne K, Somers R, Marr A. Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid. Cancer Biomark 2005;1:59-67
128. Aicher L, Wahl D, Arce A, et al. New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis 1998;19:1998-2003 (Pubitemid 28392245)
129. Aicher L, Meier G, Norcross AJ, et al. Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochem Pharmacol 1997;53:723-31 (Pubitemid 27148250)
130. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-60 (Pubitemid 40664306)
131. Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006;44:288-91 (Pubitemid 43357687)
132. Le Bricon T, Thervet E, Benlakehal M, et al. Changes in plasma cystatin C after renal transplantation and acute rejection in adults. Clin Chem 1999;45:2243-9
133. Yang GP, Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991;2:351-7
134. Muramatsu Y, Tsujie M, Kohda Y, et al. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002;62:1601-10 (Pubitemid 35286267)
135. Sundberg AG, Nilsson R, Appelkvist EL, Dallner G. Immuno-histochemical localization of alpha and pi class glutathione transferases in normal human tissues. Pharmacol Toxicol 1993;72:321-31 (Pubitemid 23181618)
136. Sundberg AG, Appelkvist EL, Backman L, Dallner G. Urinary pi-class glutathione transferase as an indicator of tubular damage in the human kidney. Nephron 1994;67:308-16
137. Backman L, Appelkvist EL, Ringden O, Dallner G. Glutathione transferase in the urine: a marker for post-transplant tubular lesions. Kidney Int 1988;33:571-7 (Pubitemid 18075684)
138. Harrison DJ, Kharbanda R, Cunningham DS, et al. Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury. J Clin Pathol 1989;42:624-8 (Pubitemid 19156433)
139. Eijkenboom JJ, van Eijk LT, Pickkers P, et al. Small increases in the urinary excretion of glutathione S-transferase A1 and P1 after cardiac surgery are not associated with clinically relevant renal injury. Intensive Care Med 2005;31:664-7 (Pubitemid 40684984)
140. Pelsers MM. Fatty acid-binding protein as marker for renal injury. Scand J Clin Lab Invest 2008;241(Suppl):73-7 (Pubitemid 351883662)
141. Sanchez-Pozos K, Lee-Montiel F, Perez-Villalva R, et al. Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity. Nephrol Dial Transplant 2010;25:2150-8
142. Fernandes I, Zhang Y, Qi Y, et al. Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity. Transplantation 2009;88:1323-31
143. Perez-Rojas J, Blanco JA, Cruz C, et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007;292:F131-9
144. Ichimura T, Asseldonk EJ, Humphreys BD, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118:1657-68 (Pubitemid 351632370)
145. Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290:F517-29
146. Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-44 (Pubitemid 34754067)
147. Hong ME, Hong JC, Stepkowski S, Kahan BD. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene. Transplant Proc 2005;37:4254-8 (Pubitemid 43016003)
148. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288:285-90
149. Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid binding protein as a marker for monitoring chronic kidney disease: a multi-center trial. J Lab Clin Med 2005;145:125-33 (Pubitemid 40432361)
150. Duraj FF, Backman L, Dati F, Ringden O. Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. Transpl Int 1991;4:146-50
151. Backman L, Ringden O, Bjorkhem I, Lindback B. Increased serum beta 2 microglobulin during rejection, cyclosporine-induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients. Transplantation 1986;42:368-71 (Pubitemid 16005762)
152. Davey PG, Cowley DM, Geddes AM, Terry J. Clinical evaluation of beta 2-microglobulin, muramidase, and alanine aminopeptidase as markers of gentamicin nephrotoxicity. Contrib Nephrol 1984;42:100-6
153. Tolkoff-Rubin NE, Rubin RH, Bonventre JV. Non-invasive renal diagnostic studies. Clin Lab Med 1988;8:507-26
154. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998;9:1723-35
155. Palmieri L, Ronca G, Cioni L, Puccini R. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase, alanine aminopeptidase and lysozyme in patients with renal disease. Contrib Nephrol 1984;42:123-9
156. Diener U, Knoll E, Ratge D, et al. Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase during sequential combination chemotherapy. J Clin Chem Clin Biochem 1982;20:615-19 (Pubitemid 13160716)
157. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007;18:904-12
158. Gruber SA, Gallichio M, Rosano TG, et al. Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients. J Clin Pharmacol 1997;37:575-86 (Pubitemid 27443538)
159. Marchewka Z, Kuzniar J, Dlugosz A. Enzymatic markers of cyclosporine nephrotoxicity in patients after renal transplantation. Int Urol Nephrol 1999;31:727-34 (Pubitemid 30179131)
160. Bornstein B, Arenas J, Morales JM, et al. Cyclosporine nephrotoxicity and rejection crisis: diagnosis by urinary enzyme excretion. Nephron 1996;72:402-6 (Pubitemid 26059571)
161. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 2010;25:889-97
162. Haase M, Bellomo R, Devarajan P, et al. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012-24
163. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365(9466):1231-8 (Pubitemid 40469655)
164. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43 (Pubitemid 37169339)
165. Camara NO, Matos AC, Rodrigues DA, et al. Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity. Lancet 2001;357:856-7
166. Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem 1987;33:775-9
167. Camara NO, Matos AC, Rodrigues DA, et al. Urinary retinol binding protein is a good marker of progressive cyclosporine nephrotoxicity after heart transplant. Transplant Proc 2001;33:2129-31 (Pubitemid 33762656)
168. McDonough AA, Biemesderfer D. Does membrane trafficking play a role in regulating the sodium/hydrogen exchanger isoform 3 in the proximal tubule? Curr Opin Nephrol Hypertens 2003;12:533-41
169. Ruiz P, Tryphonopoulos P, Island E, et al. Citrulline evaluation in bowel transplantation. Transplant Proc 2010;42:54-6
170. David AI, Selvaggi G, Ruiz P, et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation 2007;84:1077-81 (Pubitemid 350125347)
171. Gondolesi G, Ghirardo S, Raymond K, et al. The value of plasma citrulline to predict mucosal injury in intestinal allografts. Am J Transplant 2006;6:2786-90 (Pubitemid 44571701)
172. David AI, Gaynor JJ, Zis PP, et al. An association of lower serum citrulline levels within 30 days of acute rejection in patients following small intestine transplantation. Transplant Proc 2006;38:1731-2 (Pubitemid 44190022)
173. Pappas PA, Tzakis AG, Gaynor JJ, et al. An analysis of the association between serum citrulline and acute rejection among 26 recipients of intestinal transplant. Am J Transplant 2004;4:1124-32 (Pubitemid 38868604)
174. Cagnola H, Scaravonati R, Cabanne A, et al. Evaluation of calprotectin level in intestinal content as an early marker for graft rejection. Transplant Proc 2010;42:57-61
175. Sindhi R, AshokKumar C, Mazariegos G, et al. Immune monitoring in small bowel transplantation. Curr Opin Organ Transplant 2010;15:349-56
176. Akpinar E, Vargas J, Kato T, et al. Fecal calprotectin level measurements in small bowel allograft monitoring: a pilot study. Transplantation 2008;85:1281-6 (Pubitemid 351670477)
177. Sudan D, Vargas L, Sun Y, et al. Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007;246:311-15 (Pubitemid 47196530)
178. Pakarinen MP, Kuusanmaki P, Lauronen J, et al. Effects of ileum transplantation and chronic rejection on absorption and synthesis of cholesterol in pigs. Pediatr Surg Int 2003;19:656-61 (Pubitemid 38081976)
179. Nikkila K, Miettinen TA, Hockerstedt KV, Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 2005;18:221-5 (Pubitemid 41743314)
180. Ritchie BK, Brewster DR, Davidson GP, et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics 2009;124:620-6
181. Johansson JE, Ekman T. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Bone Marrow Transplant 1999;24:35-9 (Pubitemid 29346602)
182. Musso CG, Michelangelo H, Vilas M, et al. Creatinine reabsorption by the aged kidney. Int Urol Nephrol 2009;41:727-31